Short Summary
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Detailed Summary
Dr. Falk Pharma GmbH (Petitioner) challenged the validity of U.S. Patent 11260061 before the PTAB, asserting obviousness over prior art references including Perrett and Dohil2009 under 35 U.S.C. § 103. The Board found that Petitioner showed a reasonable likelihood of prevailing on Ground 1 (Perrett). A key component of the decision involved claim construction, where the Board defined 'adsorbed onto a pharmaceutically acceptable carrier' as meaning 'adhered to or retained on a surface of a pharmaceutically acceptable carrier.' This finding allowed the Petitioner to advance arguments that the blending process in Perrett implicitly leads to the claimed adsorption limitation.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Dr. Falk Pharma GmbH vs Ellodi Pharmaceuticals LP is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Samsung Electronics Co., Ltd. et al.vsWilus Institute of Standards and Technology Inc.
Samsung challenged Wilus's wireless patent claims based on obviousness in view of prior art standards and publications. The PTAB institution decision found a reasonable likelihood that the claims are unpatentable, specifically citing combinations of Bharadwaj and Sun. This sets up a significant trial over HE WLAN technology.
Kangxi Communication Technologies (Shanghai) Co., Ltd.vsSKYWORKS SOLUTIONS, INC.
Kangxi Communication Technologies challenged SKYWORKS SOLUTIONS' RF switch system patent (9148194) at the PTAB, arguing obviousness over prior art references Huang and Seshimo. The Board granted institution because the petitioner showed a reasonable likelihood of prevailing on claims 1-11 based on the Huang reference. This moves the dispute into the trial phase.
LG Energy Solution, Ltd.vsMolecular Rebar Design, LLC
LG Energy Solution successfully secured the institution of its IPR against Molecular Rebar Design, LLC regarding lithium-ion battery technology. The Board found that Petitioner demonstrated a reasonable likelihood of prevailing on key claims despite arguments of obviousness over multiple prior art references.
Apple Inc.vsApex Beam Technologies LLC
Apple files an IPR petition challenging Apex Beam’s 11,626,904 patent on multi‑antenna transmission, asserting obviousness over Liu, Park, and Ng references.
BOE Technology Group Co., Ltd.vsOptronic Sciences LLC
BOE Technology Group and Optronic Sciences settled their IPR dispute over U.S. Patent 7,226,801 B2. The Board terminated the proceeding by joint motion, citing good cause and confidentiality considerations.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.